Executive summary: Updates to the dietary treatment of prediabetes and type 2 diabetes mellitus.

Adequate lifestyle changes significantly reduce the cardiovascular risk factors associated with prediabetes and type 2 diabetes mellitus. Therefore, healthy eating habits, regular physical activity, abstaining from using tobacco, and good sleep hygiene are recommended for managing these conditions. There is solid evidence that diets that are plant-based; low in saturated fatty acids, cholesterol, and sodium; and high in fiber, potassium, and unsaturated fatty acids are beneficial and reduce the expression of cardiovascular risk factors in these subjects. In view of the foregoing, the Mediterranean diet, the DASH diet, a low-carbohydrate diet, and a vegan-vegetarian diet are of note. Additionally, the relationship between nutrition and these metabolic pathologies is fundamental in targeting efforts to prevent weight gain, reducing excess weight in the case of individuals with overweight or obesity; and personalizing treatment to promote patient empowerment. This document is the executive summary of an updated review that includes the main recommendations for improving dietary nutritional quality in people with prediabetes or type 2 diabetes mellitus. The full review is available on the webpages of the Spanish Society of Arteriosclerosis (SEA, for its initials in Spanish), the Spanish Diabetes Society (SED, for its initials in Spanish), and the Spanish Society of Internal Medicine (SEMI, for its initials in Spanish).

Resumen ejecutivo: actualización en el tratamiento dietético de la prediabetes y la diabetes mellitus tipo 2 / Executive summary: Updates to the dietary treatment of prediabetes and type 2 diabetes mellitus

Los cambios adecuados del estilo de vida reducen significativamente los factores de riesgo cardiovascular asociados a la prediabetes y la diabetes mellitus tipo 2, por lo que en su manejo se debe recomendar un patrón saludable de alimentación, actividad física regular, no consumir tabaco, y una buena higiene del sueño. Hay una sólida evidencia de que los patrones alimentarios de base vegetal, bajos en ácidos grasos saturados, colesterol y sodio, con un alto contenido en fibra, potasio y ácidos grasos insaturados, son beneficiosos y reducen la expresión de los factores de riesgo cardiovascular en estos sujetos. En este contexto destacan la dieta mediterránea, la dieta DASH, la dieta baja en hidratos de carbono y la dieta vegano-vegetariana. Adicionalmente, en la relación entre nutrición y estas enfermedades metabólicas es fundamental dirigir los esfuerzos a prevenir la ganancia de peso o a reducir su exceso en caso de sobrepeso u obesidad, y personalizar el tratamiento para favorecer el empoderamiento del paciente.Este documento es un resumen ejecutivo de una revisión actualizada que incluye las principales recomendaciones para mejorar la calidad nutricional de la alimentación en las personas con prediabetes o diabetes mellitus tipo 2, disponible en las páginas web de la Sociedad Española de Arteriosclerosis, la Sociedad Española de Diabetes y la Sociedad Española de Medicina Interna.(AU)

Adequate lifestyle changes significantly reduce the cardiovascular risk factors associated with prediabetes and type 2 diabetes mellitus. Therefore, healthy eating habits, regular physical activity, abstaining from using tobacco, and good sleep hygiene are recommended for managing these conditions. There is solid evidence that diets that are plant-based; low in saturated fatty acids, cholesterol, and sodium; and high in fiber, potassium, and unsaturated fatty acids are beneficial and reduce the expression of cardiovascular risk factors in these subjects. In view of the foregoing, the Mediterranean diet, the DASH diet, a low-carbohydrate diet, and a vegan-vegetarian diet are of note. Additionally, the relationship between nutrition and these metabolic pathologies is fundamental in targeting efforts to prevent weight gain, reducing excess weight in the case of individuals with overweight or obesity, and personalizing treatment to promote patient empowerment.This document is the executive summary of an updated review that includes the main recommendations for improving dietary nutritional quality in people with prediabetes or type 2 diabetes mellitus. The full review is available on the webpages of the Spanish Society of Arteriosclerosis, the Spanish Diabetes Society, and the Spanish Society of Internal Medicine.(AU)

Resumen ejecutivo: actualización en el tratamiento dietético de la prediabetes y la diabetes mellitus tipo 2 / Executive summary: Updates to the dietary treatment of prediabetes and type 2 diabetes mellitus

Los cambios adecuados del estilo de vida reducen significativamente los factores de riesgo cardiovascular asociados a la prediabetes y la diabetes mellitus tipo 2, por lo que en su manejo se debe recomendar un patrón saludable de alimentación, actividad física regular, no consumir tabaco, y una buena higiene del sueño. Hay una sólida evidencia de que los patrones alimentarios de base vegetal, bajos en ácidos grasos saturados, colesterol y sodio, con un alto contenido en fibra, potasio y ácidos grasos insaturados, son beneficiosos y reducen la expresión de los factores de riesgo cardiovascular en estos sujetos. En este contexto destacan la dieta mediterránea, la dieta DASH, la dieta baja en hidratos de carbono y la dieta vegano-vegetariana. Adicionalmente, en la relación entre nutrición y estas enfermedades metabólicas es fundamental dirigir los esfuerzos a prevenir la ganancia de peso o a reducir su exceso en caso de sobrepeso u obesidad, y personalizar el tratamiento para favorecer el empoderamiento del paciente. Este documento es un resumen ejecutivo de una revisión actualizada que incluye las principales recomendaciones para mejorar la calidad nutricional de la alimentación en las personas con prediabetes o diabetes mellitus tipo 2, disponible en las páginas web de la Sociedad Española de Arteriosclerosis, la Sociedad Española de Diabetes y la Sociedad Española de Medicina Interna (AU)

Adequate lifestyle changes significantly reduce the cardiovascular risk factors associated with prediabetes and type 2 diabetes mellitus. Therefore, healthy eating habits, regular physical activity, abstaining from using tobacco, and good sleep hygiene are recommended for managing these conditions. There is solid evidence that diets that are plant-based; low in saturated fatty acids, cholesterol, and sodium; and high in fiber, potassium, and unsaturated fatty acids are beneficial and reduce the expression of cardiovascular risk factors in these subjects. In view of the foregoing, the Mediterranean diet, the DASH diet, a low-carbohydrate diet, and a vegan-vegetarian diet are of note. Additionally, the relationship between nutrition and these metabolic pathologies is fundamental in targeting efforts to prevent weight gain, reducing excess weight in the case of individuals with overweight or obesity, and personalizing treatment to promote patient empowerment. This document is the executive summary of an updated review that includes the main recommendations for improving dietary nutritional quality in people with prediabetes or type 2 diabetes mellitus. The full review is available on the webpages of the Spanish Society of Arteriosclerosis, the Spanish Diabetes Society, and the Spanish Society of Internal Medicine (AU)

Executive summary: Updates to the dietary treatment of prediabetes and type 2 diabetes mellitus. / Resumen ejecutivo: actualización en el tratamiento dietético de la prediabetes y la diabetes mellitus tipo 2.

Adequate lifestyle changes significantly reduce the cardiovascular risk factors associated with prediabetes and type 2 diabetes mellitus. Therefore, healthy eating habits, regular physical activity, abstaining from using tobacco, and good sleep hygiene are recommended for managing these conditions. There is solid evidence that diets that are plant-based; low in saturated fatty acids, cholesterol, and sodium; and high in fiber, potassium, and unsaturated fatty acids are beneficial and reduce the expression of cardiovascular risk factors in these subjects. In view of the foregoing, the Mediterranean diet, the DASH diet, a low-carbohydrate diet, and a vegan-vegetarian diet are of note. Additionally, the relationship between nutrition and these metabolic pathologies is fundamental in targeting efforts to prevent weight gain, reducing excess weight in the case of individuals with overweight or obesity, and personalizing treatment to promote patient empowerment. This document is the executive summary of an updated review that includes the main recommendations for improving dietary nutritional quality in people with prediabetes or type 2 diabetes mellitus. The full review is available on the webpages of the Spanish Society of Arteriosclerosis, the Spanish Diabetes Society, and the Spanish Society of Internal Medicine.

Executive summary: Updates to the dietary treatment of prediabetes and type 2 diabetes mellitus. / Resumen ejecutivo: actualización en el tratamiento dietético de la prediabetes y la diabetes mellitus tipo 2.

Adequate lifestyle changes significantly reduce the cardiovascular risk factors associated with prediabetes and type 2 diabetes mellitus. Therefore, healthy eating habits, regular physical activity, abstaining from using tobacco, and good sleep hygiene are recommended for managing these conditions. There is solid evidence that diets that are plant-based; low in saturated fatty acids, cholesterol, and sodium; and high in fiber, potassium, and unsaturated fatty acids are beneficial and reduce the expression of cardiovascular risk factors in these subjects. In view of the foregoing, the Mediterranean diet, the DASH diet, a low-carbohydrate diet, and a vegan-vegetarian diet are of note. Additionally, the relationship between nutrition and these metabolic pathologies is fundamental in targeting efforts to prevent weight gain, reducing excess weight in the case of individuals with overweight or obesity, and personalizing treatment to promote patient empowerment. This document is the executive summary of an updated review that includes the main recommendations for improving dietary nutritional quality in people with prediabetes or type 2 diabetes mellitus. The full review is available on the webpages of the Spanish Society of Arteriosclerosis, the Spanish Diabetes Society, and the Spanish Society of Internal Medicine.

¿Han influido el algoritmo de prescripción de la Administración y las guías de manejo de la dislipemia de la ACC/AHA 2013 en el manejo de la dislipemia? Proyecto MEJORA-LO CV / Have the Government's prescription algorithm and the 2013 American College of Cardiology/American Heart Association guidelines for managing dyslipidaemia influenced the management of dyslipidaemia? The MEJORALO-CV Project

OBJETIVO: Conocer el manejo de la dislipemia en atención primaria tras la publicación de la Guía de la American College of Cardiology/American Heart Association (ACC/AHA) del año 2013 y el algoritmo de la Administración. MÉTODO: Estudio transversal descriptivo con encuesta a médicos de atención primaria de la Comunidad Valenciana entre enero y octubre de 2016. RESULTADOS: Participaron 199 facultativos con una media (desviación típica) de 48,9 (11) años de edad y 21,3 (11,1) años de experiencia. Las guías más seguidas eran las de la European Society of Cardiology (37,5%) y las de la Administración (23,4%). El 6,3% seguía la de la ACC/AHA 2013. El 88% establecía objetivos según colesterol LDL y riesgo cardiovascular. La elección del hipolipemiante estaba basada en su capacidad reductora de colesterol LDL (28,6%), algoritmo de la Administración (23,4%) y seguridad (20,4%). Estatinas, ezetimiba y fibratos eran los hipolipemiantes preferidos, y la combinación (51%) e incremento de dosis (35%) las estrategias en ausencia de control. Se determinaba perfil lipídico, transaminasas y creatincinasa cada 6 (59,5; 52,3 y 54,3%, respectivamente) o 12 meses (25,1; 29,2 y 30,3%, respectivamente). Un 41% era conocedor de la polémica con la Guía ACC/AHA 2013, y aunque un 60% reconocía su relevancia, solo un 21% modificó su quehacer diario por ella. CONCLUSIONES: El algoritmo de la Administración tuvo mayor impacto que la Guía ACC/AHA 2013 en atención primaria. Campos de mejora fueron el bajo uso de guías y tablas de riesgo validadas, y racionalización de la periodicidad de las analíticas

OBJECTIVE: To determine the management of dyslipidaemia in primary care after the publication of the American College of Cardiology/American Heart Association (ACC/AHA) 2013 guidelines and Valencian government's algorithm. METHOD: We conducted a cross-sectional descriptive study that employed a survey of primary care physicians of the Community of Valencia between January and October 2016. RESULTS: A total of 199 physicians (mean age, 48.9±11.0 years; experience, 21.3±11.1 years) participated in the survey. The most followed guidelines were those of the European Society of Cardiology (37.5% of respondents) and Valencian government (23.4% of respondents). Some 6.3% of the respondents followed the 2013 ACC/AHA guidelines, and 88.0% established objectives based on LDL cholesterol and cardiovascular risk. The choice of lipid-lowering drug was based on its LDL cholesterol lowering capacity (28.6% of respondents), on the Valencian government's algorithm (23.4%) and on the drug's safety (20.4%). Statins, ezetimibe and fibrates were the preferred hypolipemiant agents, and their combination (51% of respondents) and dosage increases (35%) were the strategies employed for poor control. Lipid profile and transaminase and creatine kinase levels were measured every 6 (59.5%, 52.3% and 54.3% of respondents, respectively) or 12 months (25.1%, 29.2% and 30.3%, respectively). Forty-one percent of the respondents were aware of the controversy surrounding the 2013 ACC/AHA guidelines. Although 60% of the respondents acknowledged its relevance, only 21% changed their daily practices accordingly. CONCLUSIONS: The Valencian government's algorithm had a greater impact than the 2013 ACC/AHA guidelines in primary care in Valencia. Areas for improvement included the low use of validated guidelines and risk tables and the streamlining of laboratory test periodicity

Have the Government's prescription algorithm and the 2013 American College of Cardiology/American Heart Association guidelines for managing dyslipidaemia influenced the management of dyslipidaemia? The MEJORALO-CV Project. / ¿Han influido el algoritmo de prescripción de la Administración y las guías de manejo de la dislipemia de la ACC/AHA 2013 en el manejo de la dislipemia? Proyecto MEJORA-LO CV.

OBJECTIVE: To determine the management of dyslipidaemia in primary care after the publication of the American College of Cardiology/American Heart Association (ACC/AHA) 2013 guidelines and Valencian government's algorithm. METHOD: We conducted a cross-sectional descriptive study that employed a survey of primary care physicians of the Community of Valencia between January and October 2016. RESULTS: A total of 199 physicians (mean age, 48.9±11.0 years; experience, 21.3±11.1 years) participated in the survey. The most followed guidelines were those of the European Society of Cardiology (37.5% of respondents) and Valencian government (23.4% of respondents). Some 6.3% of the respondents followed the 2013 ACC/AHA guidelines, and 88.0% established objectives based on LDL cholesterol and cardiovascular risk. The choice of lipid-lowering drug was based on its LDL cholesterol lowering capacity (28.6% of respondents), on the Valencian government's algorithm (23.4%) and on the drug's safety (20.4%). Statins, ezetimibe and fibrates were the preferred hypolipemiant agents, and their combination (51% of respondents) and dosage increases (35%) were the strategies employed for poor control. Lipid profile and transaminase and creatine kinase levels were measured every 6 (59.5%, 52.3% and 54.3% of respondents, respectively) or 12 months (25.1%, 29.2% and 30.3%, respectively). Forty-one percent of the respondents were aware of the controversy surrounding the 2013 ACC/AHA guidelines. Although 60% of the respondents acknowledged its relevance, only 21% changed their daily practices accordingly. CONCLUSIONS: The Valencian government's algorithm had a greater impact than the 2013 ACC/AHA guidelines in primary care in Valencia. Areas for improvement included the low use of validated guidelines and risk tables and the streamlining of laboratory test periodicity.

Pharmacological management of dyslipidemia in high and very high cardiovascular risk patients.

Dyslipaemia is one of the main risk factors in the development of cardiovascular diseases. Currently, there are different alternatives available (amongst which statins occupy a pre-eminent place), to optimise the treatment of patients at high or very high cardiovascular risk. Despite this, the percentage of patients that achieve good lipid control is low. The causes of the mismatch with proposed objectives include lack of patient adherence and therapeutic inertia. This review uses available evidence and the latest clinical guides as a basis to assess the pharmacological treatment of dyslipaemia in patients with a background of arteriosclerotic vascular disease, diabetes, chronic kidney disease, cardiovascular risk at ≥5% calculated by SCORE and familial hypercholesterolaemia. The treatment of hypertriglyceridemia is also reviewed along with the special consideration that poly-pharmacy deserves in patients treated with statins, making mention of the treatment of dyslipaemia with HIV infection. The global assessment of cardiovascular risk is of high priority to adapt treatment to the specific objectives of the c-LDL for each risk category.

Pacientes de alto riesgo cardiovascular. ¿Se pueden suprimir los hipolipemiantes? / No disponible

No disponible

Tratamiento farmacológico de la dislipemia en pacientes de alto y muy alto riesgo cardiovascular / Pharmacological management of dyslipidemia in high and very high cardiovascular risk patients

La dislipemia es uno de los principales factores de riesgo para el desarrollo de enfermedades cardiovasculares. Actualmente disponemos de diferentes alternativas (entre las que las estatinas ocupan un lugar preeminente), para optimizar el tratamiento en los pacientes de alto y muy alto riesgo cardiovascular. A pesar de ello, el porcentaje de pacientes que consigue un buen control lipídico es bajo, entre las causas de la inadecuación a los objetivos propuestos, figuran: la falta de adherencia del paciente y la inercia terapéutica. En esta revisión se valora en base a las evidencias disponibles y a las últimas guías clínicas, el tratamiento farmacológico de la dislipemia en pacientes con antecedentes de enfermedad vascular arteriosclerótica, diabetes, enfermedad renal crónica, riesgo cardiovascular ≥5% calculado por SCORE e hipercolesterolemia familiar. También se revisa el tratamiento de la hipertrigliceridemia y la consideración especial que merece la polimedicación en pacientes tratados con estatinas, haciendo mención al tratamiento de la dislipemia en aquellos con infección por VIH. La evaluación global del riesgo cardiovascular es prioritaria para adecuar el tratamiento a los objetivos específicos del c- LDL para cada categoría de riesgo (AU)

Dyslipaemia is one of the main risk factors in the development of cardiovascular diseases. Currently, there are different alternatives available (amongst which statins occupy a pre-eminent place), to optimise the treatment of patients at high or very high cardiovascular risk. Despite this, the percentage of patients that achieve good lipid control is low. The causes of the mismatch with proposed objectives include lack of patient adherence and therapeutic inertia. This review uses available evidence and the latest clinical guides as a basis to assess the pharmacological treatment of dyslipaemia in patients with a background of arteriosclerotic vascular disease, diabetes, chronic kidney disease, cardiovascular risk at ≥5% calculated by SCORE and familial hypercholesterolaemia. The treatment of hypertriglyceridemia is also reviewed along with the special consideration that poly-pharmacy deserves in patients treated with statins, making mention of the treatment of dyslipaemia with HIV infection. The global assessment of cardiovascular risk is of high priority to adapt treatment to the specific objectives of the c-LDL for each risk category (AU)

[Could the moderate consumption of beer be included within a healthy diet?]. / ¿El consumo moderado de cerveza podría incluirse dentro de una alimentación saludable?

INTRODUCTION: Beer is a beverage that has been usually included in our habitual diet from immemorial time. However, beer consumption depends on food habits and lifestyle in different populations. In Mediterranean countries, fermented beverages like beer, takes up a key space in the Mediterranean diet that has been declared in 2010 as Cultural Immaterial World Heritage by UNESCO. OBJECTIVES: The positioning where the Spanish Society of Primary Care Medicine and the Beer and Health Information Centre have conjointly worked on has the following beer consumption-related aims: a) to update its knowledge based on the scientific evidence; b) to evaluate the possibility to include it within a healthy diet for healthy adults; c) to inform health professionals and the general population about its possible health benefits. METHODOLOGY: A panel of experts, represented by clinicians and researchers in the field of nutrition held a meeting with the purpose to review the scientific literature related to the effects of the moderate consumption of fermented beverages, particularly beer, and to reach a consensus on the results, conclusions and recommendations suggested and established by other experts at an international level. RESULTS: The current scientific evidence reflects that moderate consumption of beer does not affect anthropometry related variables. Although energy supply from beer is very low, its nutrients and bioactive compound contents are interesting, since its potential antioxidant effect together with the fact that anti-carcinogenic, anti-inflammatory and anti-viral effects have been demonstrated, as well as its beneficial effect on cardiovascular health, leading to a greater protection than even in the abstemious population. CONCLUSIONS: In view of the results obtained from the literature consulted by the expert panel, we can conclude that the moderate consumption of beer can be considered within a healthy diet. Nevertheless, the general recommendation is addressed only to healthy adults, never to children, adolescents or pregnant women. In the case of elderly people, any beverage containing alcohol should not be recommended for those who are treated with drugs in order to avoid possible interactions with alcohol consumption.

Dislipidemia y riesgo vascular. Una revisión basada en nuevas evidencias / Dyslipidaemia and vascular risk. A new evidence based review

La dislipidemia es uno de los principales factores de riesgo de cardiopatía isquémica, primera causa de mortalidad en el mundo. Realizar una detección temprana y una intervención terapéutica precoz son elementos clave a la hora de establecer una adecuada prevención de una enfermedad cardiovascular. Debemos conocer el arsenal terapéutico de que disponemos para su adecuada utilización en cada una de las situaciones clínicas que puedan presentar nuestros pacientes. En los últimos 3 años, la proliferación de múltiples guías para el manejo clínico del paciente dislipidémico con aparentes mensajes contradictorios en relación con la consecución de los objetivos de control llegan a confundir a los médicos. En esta revisión se pretende ofrecer una visión actualizada de la situación de la dislipidemia, partiendo del posicionamiento de las guías tanto europeas como americanas, pasando por diferentes situaciones de riesgo y finalizando con el concepto de dislipidemia aterogénica, reconocido factor de riesgo cardiovascular (AU)

Dyslipidaemia is one of the major risk factors for ischaemic heart disease, the leading cause of death worldwide. Early detection and therapeutic intervention are key elements in the adequate prevention of cardiovascular disease. It is essential to have knowledge of the therapeutic arsenal available for their appropriate use in each of the clinical situations that might be presented in our patients. In the past 3 years, there has been a proliferation of multiple guidelines for the clinical management of patients with dyslipidaemia, with apparent contradictory messages regarding the achievement of the control objectives, which are confusing clinicians. This review aims to provide an updated overview of the situation as regards dyslipidaemia, based on the positioning of both European and American guidelines, through different risk situations and ending with the concept of atherogenic dyslipidaemia as a recognized cardiovascular risk factor (AU)

¿El consumo moderado de cerveza podría incluirse dentro e una alimentación saludable? / Could the moderate consumption of beer be included within a healthy diet?

Introducción: La cerveza es una bebida que lleva formando parte de nuestra vida habitual desde tiempos inmemoriales. Sin embargo, su consumo depende de los hábitos alimentarios y del estilo de vida de las distintas poblaciones. En los países europeos situados en la cuenca mediterránea, las bebidas fermentadas como la cerveza ocupan un lugar clave en la dieta mediterránea, declarada en 2010 como Patrimonio Cultural Inmaterial de la Humanidad por la UNESCO. Objetivos: El posicionamiento en el que colaboran de forma conjunta un grupo de expertos de la Sociedad Española de Médicos de Atención Primaria (SEMERGEN) y el Centro de Información Cerveza y Salud (CICS) tiene como objetivos, en relación con el consumo moderado de cerveza: a) actualizar el conocimiento basado en la evidencia científica; b) valorar la posibilidad de incluirlo dentro de una alimentación saludable para adultos sanos; c) informar sobre sus posibles beneficios a los profesionales de la salud y a la población en general. Metodología: Un panel de expertos, representado por clínicos e investigadores en el campo de la nutrición, se reunió para revisar la literatura científica relacionada con los efectos del consumo moderado de bebidas fermentadas, en particular de la cerveza, y consensuar resultados, conclusiones y recomendaciones emitidas por distintos autores en el ámbito internacional. Resultados: La evidencia científica actual refleja que el consumo moderado de cerveza no modifica los parámetros relacionados con la antropometría, tanto los pliegues cutáneos como el peso se mantienen. Su aporte energético es bajo, aunque el contenido en nutrientes y compuestos bioactivos es muy interesante, ya que se ha demostrado su potencial efecto antioxidante, anticarcinogénico, antiinflamatorio y antiviral, así como su efecto beneficioso sobre la salud cardiovascular, obteniéndose con ingestas moderadas una protección mayor que en población abstemia. Conclusiones: A la vista de los resultados obtenidos tras la consulta bibliográfica realizada por el panel de expertos, se puede concluir que el consumo moderado de cerveza puede considerarse como parte de una alimentación saludable. No obstante, el consumo moderado de cerveza tradicional está contemplado en adultos sanos, nunca en menores de edad, mujeres gestantes o personas mayores con medicación susceptible de interaccionar con la ingesta de alcohol (AU)

Introduction: Beer is a beverage that has been usually included in our habitual diet from immemorial time. However, beer consumption depends on food habits and lifestyle in different populations. In Mediterranean countries, fermented beverages like beer, takes up a key space in the Mediterranean diet that has been declared in 2010 as Cultural Immaterial World Heritage by UNESCO. Objectives: The positioning where the Spanish Society of Primary Care Medicine and the Beer and Health Information Centre have conjointly worked on has the following beer consumption-related aims: a) to update its knowledge based on the scientific evidence; b) to evaluate the possibility to include it within a healthy diet for healthy adults; c) to inform health professionals and the general population about its possible health benefits. Methodology: A panel of experts, represented by clinicians and researchers in the field of nutrition held a meeting with the purpose to review the scientific literature related to the effects of the moderate consumption of fermented beverages, particularly beer, and to reach a consensus on the results, conclusions and recommendations suggested and established by other experts at an international level. Results: The current scientific evidence reflects that moderate consumption of beer does not affect anthropometry related variables. Although energy supply from beer is very low, its nutrients and bioactive compound contents are interesting, since its potential antioxidant effect together with the fact that anti-carcinogenic, anti-inflammatory and anti-viral effects have been demonstrated, as well as its beneficial effect on cardiovascular health, leading to a greater protection than even in the abstemious population. Conclusions: In view of the results obtained from the literature consulted by the expert panel, we can conclude that the moderate consumption of beer can be considered within a healthy diet. Nevertheless, the general recommendation is addressed only to healthy adults, never to children, adolescents or pregnant women. In the case of elderly people, any beverage containing alcohol should not be recommended for those who are treated with drugs in order to avoid possible interactions with alcohol consumption (AU)

[Dyslipidaemia and vascular risk. A new evidence based review]. / Dislipidemia y riesgo vascular. Una revisión basada en nuevas evidencias.

Dyslipidaemia is one of the major risk factors for ischaemic heart disease, the leading cause of death worldwide. Early detection and therapeutic intervention are key elements in the adequate prevention of cardiovascular disease. It is essential to have knowledge of the therapeutic arsenal available for their appropriate use in each of the clinical situations that might be presented in our patients. In the past 3 years, there has been a proliferation of multiple guidelines for the clinical management of patients with dyslipidaemia, with apparent contradictory messages regarding the achievement of the control objectives, which are confusing clinicians. This review aims to provide an updated overview of the situation as regards dyslipidaemia, based on the positioning of both European and American guidelines, through different risk situations and ending with the concept of atherogenic dyslipidaemia as a recognized cardiovascular risk factor.

[New concepts in dietary treatment of metabolic syndrome]. / Nuevos conceptos en el tratamiento dietético del síndrome metabólico.

Metabolic syndrome is a disorder having high prevalence in our society. It is characterized by different proatherogenic disorders (dyslipidemia, arterial hypertension, hydrocarbonated intolerance, prothrombotic and proinflammatory conditions) and predisposing factors (central obesity, sedentary life and genetic factors). There is much evidence in favor of the changes in the style of life in the control of metabolic and non-metabolic parameters that characterize this syndrome. The role of certain foods in the prevention and treatment of the manifestations of the metabolic syndrome, among others, coffee, vegetable and marine sterols, nuts, pod vegetables, eggs and olive oil, are presently the object of debate. Herein, the new dietary concepts for patients with metabolic syndrome and the scientific evidence supporting them are reviewed.

Nuevos conceptos en el tratamiento dietético del síndrome metabólico / New concepts in dietary treatment of metabolic syndrome

El síndrome metabólico es un trastorno de elevada prevalencia en nuestra sociedad caracterizado por diversas alteraciones proaterogénicas (dislipidemia, hipertensión arterial, intolerancia hidrocarbonada, estados protrombótico y proinflamatorio) y factores predisponentes (obesidad central, sedentarismo y factores genéticos). Existen numerosas evidencias a favor de los cambios del estilo de vida en el control de los parámetros metabólicos y no metabólicos que caracterizan este síndrome. Actualmente es objeto de debate el papel de determinados alimentos en la prevención y tratamiento de las manifestaciones del síndrome metabólico, entre otros el café, los esteroles vegetales y marinos, los frutos secos, las legumbres, los huevos y el aceite de oliva. Aquí se revisan los nuevos conceptos dietéticos para pacientes con síndrome metabólico y las evidencias científicas que los apoyan

Metabolic syndrome is a disorder having high prevalence in our society. It is characterized by different proatherogenic disorders (dyslipidemia, arterial hypertension, hydrocarbonated intolerance, prothrombotic and proinflammatory conditions) and predisposing factors (central obesity, sedentary life and genetic factors). There is much evidence in favor of the changes in the style of life in the control of metabolic and non-metabolic parameters that characterize this syndrome. The role of certain foods in the prevention and treatment of the manifestations of the metabolic syndrome, among others, coffee, vegetable and marine sterols, nuts, pod vegetables, eggs and olive oil, are presently the object of debate. Herein, the new dietary concepts for patients with metabolic syndrome and the scientific evidence supporting them are reviewed